Novo Nordisk Reports Positive Semaglutide Trial Results for Obesity Treatment in Children
Novo Nordisk (NVO) announced positive results from a phase 3 clinical trial of semaglutide, its obesity drug, in children aged 6 to under 12. The study found that 40.4% of the 165 participants were no longer classified as obese after 68 weeks of treatment. This marks an important milestone for Novo Nordisk and could expand the market potential for semaglutide beyond adults. The trial, known as STEP Young, met its primary endpoint, reinforcing confidence in the drug's efficacy across a broader age range. The results may influence regulatory decisions regarding pediatric use and open new revenue streams for the company. Investors are likely to view these findings positively due to their potential market expansion implications.
Tickers: $NVO
Topics: children's health clinical trials obesity treatment semaglutide